Fda Nih 2024 D1s05 Overview

This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ...

This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ...

This presentation reviewed

This presentation provided an

This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ...

This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ...

This presentation discussed a rundown of the Do's and Don'ts from

This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ...

This presentation demonstrated drug listing update and listing certification requirements, describing what information must be ...

This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ...

This presentation demonstrated creating a listing SPL through CDER Direct and enumerated data elements required for drug ...

This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

This presentation described drug listing requirements under 21 CFR 207 and identified common listing issues encountered during ...

This inaugural webinar was a collaborative effort between

The last of three Q&A discussion panels from the

The first of three Q&A discussion panels from the

This presentation explored regulatory resources and avenues for obtaining early guidance from CBER's Office of Therapeutic ...

This presentation explained the assignment of NDCs to drugs and described the history of the National Drug Code system.

This video provided an